Basic Information
Curzion Pharmaceuticals is a privately held, development-stage biopharmaceutical company developing CZN001 (renamed HZN-825), an oral, selective lysophosphatidic acid receptor 1 (LPAR1) antagonist.
Curzion Pharmaceuticals
SanDiego,California,United States of America
less than 15 people
January 01, 2019
--
--